Contemporary real-world treatment of cardiac transthyretin amyloidosis with tafamidis: a long-term multicentre study
ESC Heart Failure · 27.08.2026 · 13 (5)
DOI: 10.1093/eschf/xvag211 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift ESC Heart Failure, online erschienen am 30.07.2026. Verfasst von Richard J Nies und 22 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne, Kerpener Straße 62, Cologne 50937, Germ…. Hauptthemen laut MEDLINE: Benzoxazoles, Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Würzburg and Tomtec Imaging Systems, Bavarian Ministry of Economic Affairs, Regional Development and Energy, Cardio-immune interfaces.
Abstract (Originalsprache)
Aims
Tafamidis was the first drug approved for transthyretin amyloid cardiomyopathy (ATTR-CM), but contemporary real-world evidence is lacking. Methods and results This retrospective, multicentre study included ATTR-CM patients enrolled after commercial availability of tafamidis 61 mg in Germany (April 2020 to March 2021), with treatment initiation based on physician clinical judgement. Primary and secondary endpoints were all-cause mortality and the composite of all-cause mortality and/or heart failure (HF) hospitalization, respectively. The cohort comprised 329 patients (median age 80 [76–83] years, 85% male and 8% variant ATTR) and 80% received tafamidis. During a median follow-up of 39 [18–48] months, 21% of patients died and 42% reached the composite endpoint. Tafamidis-treated patients had a 3-year survival of 86% and an event-free survival of 63%. After propensity-score matching for age, New York Heart Association (NYHA) class, National Amyloidosis Centre (NAC) stage, and serum albumin, tafamidis was significantly associated with lower all-cause mortality (hazard ratio [HR] 0.28; 95%-confidence interval [CI] 0.13–0.61; P = .001) and fewer composite events (HR 0.56; 95%-CI 0.33–0.97; P = .039). In tafamidis-treated patients, primary and secondary endpoints were associated with advanced NAC stage (P < .031; P < .009), age ≥80 years (P = .022; P = .004), and serum albumin ≤42.5 g/L (P = .015; P < .001), whereas NYHA class ≥III predicted only the composite endpoint (P = .059; P < .001).
Conclusions
This study provides long-term real-world outcome data for ATTR-CM patients treated with tafamidis based on physician clinical judgement. Adverse outcomes were strongly predicted by low serum albumin, advanced NAC stage, and older age, emphasizing the importance of early diagnosis and timely therapy of ATTR-CM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne, Kerpener Straße 62, Cologne 50937, Germany.
- Department of Internal Medicine III, University Hospital Saarland, Saarland University, Homburg 66421, Germany.
- Department of Internal Medicine II - Cardiology, Sana Klinikum Berlin-Lichtenberg, Berlin 10365, Germany.
- Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Charitéplatz 1, Berlin 10117, Germany.
- Klinik für Neurologie mit Experimenteller Neurologie, Charité Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany.
- Charité-Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany.
ORCID-Profile: Richard J Nies, Fabian Knebel, Lars Michel, Tienush Rassaf, Vladimir Cejka, Michael Paulus, Bishwas Chamling, Caroline Morbach, Roman Pfister
Förderung
- University of Würzburg and Tomtec Imaging Systems
- Bavarian Ministry of Economic Affairs, Regional Development and Energy
- Cardio-immune interfaces
- Faculty of Medicine, University of Duisburg-Essen
- German Research Foundation
Zitieren
APA
Nies, R. J., Ney, S., Kindermann, I., Bewarder, Y., Zimmer, A., Knebel, F., Hahn, K., Spethmann, S., Luedike, P., Michel, L., Rassaf, T., Papathanasiou, M., Störk, S., Cejka, V., Polzin, A., Voß, F., Unsöld, B., Meindl, C., Paulus, M., …, & Pfister, R. (2026). Contemporary real-world treatment of cardiac transthyretin amyloidosis with tafamidis: a long-term multicentre study. ESC Heart Failure, 13(5). https://doi.org/10.1093/eschf/xvag211
Vancouver
Nies RJ, Ney S, Kindermann I, Bewarder Y, Zimmer A, Knebel F, et al. Contemporary real-world treatment of cardiac transthyretin amyloidosis with tafamidis: a long-term multicentre study. ESC Heart Failure. 2026;13(5). doi:10.1093/eschf/xvag211
BibTeX
@article{Nies2026,
author = {Nies, Richard J and Ney, Svenja and Kindermann, Ingrid and Bewarder, Yvonne and Zimmer, Angela and Knebel, Fabian and Hahn, Katrin and Spethmann, Sebastian and Luedike, Peter and Michel, Lars and Rassaf, Tienush and Papathanasiou, Maria and Störk, Stefan and Cejka, Vladimir and Polzin, Amin and Voß, Fabian and Unsöld, Bernhard and Meindl, Christine and Paulus, Michael and Yilmaz, Ali and Chamling, Bishwas and Morbach, Caroline and Pfister, Roman},
title = {Contemporary real-world treatment of cardiac transthyretin amyloidosis with tafamidis: a long-term multicentre study},
journal = {ESC Heart Failure},
year = {2026},
volume = {13},
number = {5},
doi = {10.1093/eschf/xvag211}
}
EUVIMED